Login
$ACHV
$6.06 -$0.26 (4.11%) Close

$ACHV 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT)

01 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 1, 2026, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Benjamin Halladay as the Company’s Chief Financial Officer and “principal financial officer,” ef...

14 Aug 2026 8-K: Other Events

Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent (the “Agent”), shares of the Comp...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval

06 Jul 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Achieve Life Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY:

02 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 29, 2026, the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date. Mr. Marrow h...

12 May 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants

16 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 15, 2026, by and among Achieve Life Sciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreemen...

24 Mar 2026 8-K: Results of Operations and Financial Condition

Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing

06 Nov 2025 8-K: Results of Operations and Financial Condition

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation

07 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 11, 2025, Achieve Life Sciences, Inc. (the “Company”) previously announced that Dr. Cindy Jacobs had informed the Company’s board of directors that she had elected to resign from her role as the Company’s Chief Medical Offic...

11 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation

On September 5, 2025, Dr. Cindy Jacobs informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that she has elected to resign from her role as the Company’s Chief Medical Officer and President, effec...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Conference Call Scheduled for 8:30 AM EDT Today, August 7, 2025

27 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

The undersigned, Achieve Life Sciences, Inc., a company incorporated under the laws of Delaware (collectively with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement as bein...

06 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of Achieve Life Sciences, Inc. (the “Company”) was held on June 4, 2025. The following is a brief description of each matter voted upon and the certified voting results.

13 May 2025 8-K: Results of Operations and Financial Condition

Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025

11 Mar 2025 8-K: Results of Operations and Financial Condition

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

10 Feb 2025 8-K: Other Events

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

10 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

On January 6, 2025, Dr. Vaughn Himes informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that he has elected to resign from his position as a member of the Board, effective immediately. Dr. Himes...

09 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation

On December 9, 2024, Achieve Life Sciences, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Mark K. Oki as the Company’s Chief Financial Officer and “principal financial officer,” effecti...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support